iRhythm/$IRTC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About iRhythm
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
- Ticker
- $IRTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,400
- Headquarters
- San Francisco, United States
- Website
- www.irhythmtech.com
iRhythm Metrics
BasicAdvanced
$3.2B
-
-$1.18
1.47
-
Price and volume
Market cap
$3.2B
Beta
1.47
52-week high
$192.47
52-week low
$82.85
Average daily volume
880K
Financial strength
Current ratio
3.567
Quick ratio
3.323
Long term debt to equity
4.002
Total debt to equity
4.098
Interest coverage (TTM)
2.92%
Profitability
EBITDA (TTM)
45.636
Gross margin (TTM)
71.89%
Net profit margin (TTM)
-4.52%
Operating margin (TTM)
4.51%
Effective tax rate (TTM)
-2.52%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
2.31%
Return on equity (TTM)
-25.81%
Valuation
Price to revenue (TTM)
3.626
Price to book
17.91
Price to tangible book (TTM)
17.99
Price to free cash flow (TTM)
419.533
Free cash flow yield (TTM)
0.24%
Free cash flow per share (TTM)
0.226
Growth
Revenue change (TTM)
21.56%
Earnings per share change (TTM)
-27.12%
3-year revenue growth (CAGR)
21.79%
10-year revenue growth (CAGR)
31.27%
3-year earnings per share growth (CAGR)
-30.07%
10-year earnings per share growth (CAGR)
-22.77%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Analyst projections of the future price of iRhythm stock.
Bulls say / Bears say
Third-quarter revenue grew 14.9% year on year, and iRhythm raised its 2026 revenue and adjusted EBITDA margin guidance. This suggests demand for its core Zio Monitor is translating into growth and stronger operating leverage. (GlobeNewswire)
The FDA-cleared third-generation algorithm is expected to cut clinician review time by up to 50% and generate about $100 million in cumulative savings over five years. If delivered, those efficiencies could support further margin gains as volumes grow. (iRhythm)
The completed VitalConnect acquisition gives iRhythm an FDA-cleared mobile cardiac telemetry product and longer-wear monitoring capabilities. The broader portfolio could help it serve more patient and care settings. (iRhythm)
Zio AT revenue was flat in the third quarter, below management’s expectations, as some customers delayed purchases while waiting for the VitalConnect integration. Management expects a further year-on-year decline in Q4, making near-term growth more dependent on the core Zio Monitor. (The Motley Fool)
iRhythm has pushed its planned Zio MCT FDA submission from 2026 into 2027 and is prioritising VitalConnect integration. That delays a key planned product and leaves execution of the combined portfolio as an important near-term test. (The Motley Fool)
Regulatory uncertainty remains: iRhythm says its FDA warning letter remediation is complete but it is still awaiting a follow-up inspection, while dialogue with the DOJ continues. Further regulatory action or prolonged review could distract management and create financial or operating risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
Upcoming events
No upcoming events
iRhythm News
AllArticlesVideos
Funds containing iRhythm
Fund name | Fund size | $IRTC weighting |
|---|---|---|
iShares Ageing Population£AGES | $887M | 0.28% |
iShares Ageing Population$AGED | $887M | 0.28% |
iShares Ageing Population€AGED | $887M | 0.28% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.11% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

